Foster Dykema Cabot & Co. Inc. MA continued to hold its stake in shares of Stryker Corporation (NYSE:SYK) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,000 shares of the medical technology company’s stock at the end of the 2nd quarter. Foster Dykema Cabot & Co. Inc. MA’s holdings in Stryker Corporation were worth $416,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the company. Bollard Group LLC raised its holdings in shares of Stryker Corporation by 0.4% in the second quarter. Bollard Group LLC now owns 832 shares of the medical technology company’s stock valued at $115,000 after purchasing an additional 3 shares during the last quarter. Assetmark Inc. raised its holdings in shares of Stryker Corporation by 0.3% in the first quarter. Assetmark Inc. now owns 1,274 shares of the medical technology company’s stock valued at $168,000 after purchasing an additional 4 shares during the last quarter. Blue Chip Partners Inc. raised its holdings in shares of Stryker Corporation by 0.3% in the first quarter. Blue Chip Partners Inc. now owns 1,775 shares of the medical technology company’s stock valued at $234,000 after purchasing an additional 6 shares during the last quarter. Guardian Life Insurance Co. of America raised its holdings in shares of Stryker Corporation by 0.8% in the first quarter. Guardian Life Insurance Co. of America now owns 1,199 shares of the medical technology company’s stock valued at $158,000 after purchasing an additional 9 shares during the last quarter. Finally, FineMark National Bank & Trust raised its holdings in shares of Stryker Corporation by 0.4% in the second quarter. FineMark National Bank & Trust now owns 3,878 shares of the medical technology company’s stock valued at $538,000 after purchasing an additional 15 shares during the last quarter. Institutional investors own 74.18% of the company’s stock.

Stryker Corporation (NYSE SYK) opened at 142.50 on Monday. Stryker Corporation has a 52-week low of $106.48 and a 52-week high of $148.84. The stock has a 50 day moving average of $144.06 and a 200-day moving average of $138.10. The company has a market capitalization of $53.30 billion, a price-to-earnings ratio of 31.81 and a beta of 0.81.

Stryker Corporation (NYSE:SYK) last released its quarterly earnings results on Thursday, July 27th. The medical technology company reported $1.53 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.51 by $0.02. Stryker Corporation had a net margin of 14.22% and a return on equity of 24.26%. The firm had revenue of $3.01 billion during the quarter, compared to analyst estimates of $2.98 billion. During the same quarter in the prior year, the firm earned $1.39 EPS. The business’s revenue for the quarter was up 6.1% compared to the same quarter last year. On average, equities research analysts anticipate that Stryker Corporation will post $6.46 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, October 31st. Stockholders of record on Friday, September 29th will be given a dividend of $0.425 per share. This represents a $1.70 annualized dividend and a dividend yield of 1.19%. The ex-dividend date is Thursday, September 28th. Stryker Corporation’s payout ratio is currently 37.95%.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.dailypolitical.com/2017/09/11/stryker-corporation-syk-position-maintained-by-foster-dykema-cabot-co-inc-ma.html.

SYK has been the subject of several analyst reports. Piper Jaffray Companies reiterated an “overweight” rating and issued a $148.00 target price on shares of Stryker Corporation in a report on Thursday, August 24th. Needham & Company LLC upgraded shares of Stryker Corporation from an “underperform” rating to a “hold” rating in a report on Friday, August 25th. Cantor Fitzgerald initiated coverage on shares of Stryker Corporation in a report on Thursday, June 29th. They issued a “neutral” rating and a $153.00 target price for the company. Morgan Stanley reiterated an “overweight” rating and issued a $160.00 target price (up previously from $155.00) on shares of Stryker Corporation in a report on Monday, July 10th. Finally, Zacks Investment Research upgraded shares of Stryker Corporation from a “hold” rating to a “buy” rating and set a $163.00 price objective for the company in a report on Monday, July 17th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $145.73.

In other news, insider Lonny J. Carpenter sold 5,000 shares of the company’s stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $146.36, for a total transaction of $731,800.00. Following the completion of the sale, the insider now owns 88,207 shares of the company’s stock, valued at approximately $12,909,976.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider David Floyd sold 19,305 shares of the company’s stock in a transaction dated Wednesday, July 12th. The shares were sold at an average price of $144.56, for a total transaction of $2,790,730.80. The disclosure for this sale can be found here. Insiders have sold a total of 25,429 shares of company stock valued at $3,686,927 in the last ninety days. Insiders own 7.40% of the company’s stock.

Stryker Corporation Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Institutional Ownership by Quarter for Stryker Corporation (NYSE:SYK)

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.